p53 polymorphism and association of human papillomavirus in oral submucous fibrosis and oral squamous cell carcinoma: A case–control study

Kaveri Hallikeri¹, Krishna Burde⁰, Venktesh Anehosur³, Bhushan B Kulkarni⁴, Shivaparakash V Hiremath⁴

Departments of ¹Oral and Maxillofacial Pathology, ²Oral Medicine and Radiology and ³Oral and Maxillofacial Surgery, S. D. M. College of Dental Sciences and Hospital, Dharwad, ⁴Department of Biotechnology and Microbiology, P. C. Jabin Post-Graduate Science College, Vidyanagar, Hubli, Karnataka, India

Abstract

Introduction: The tumor-suppressor p53 protein is inactivated by the human papillomavirus (HPV) E6 oncoprotein, causing polymorphism of the p53 at codon 72 of exon either proline (Pro) or arginine (Arg). Specific allele predisposition has been reported in the literature. The association between the p53 allele and HPV types has been reported. We analyzed the association between p53 polymorphism at codon 72 and HPV 16 and 18 genotypes in control, oral submucous fibrosis (OSF) and oral squamous cell carcinoma (OSCC).

Materials and Methods: Of the total 90 cases, biopsy tissues of all groups (30 cases of OSF, OSCC and control each) were collected to extract DNA. Polymerase chain reaction was used to detect HPV 16 and 18 and alleles of codon 72 in p53 were evaluated in all the samples.

Results: In control, OSF and OSCC samples showed the presence HPV 63.3%, 33.3% and 60%, respectively. In OSF, HPV 16 and 18 was detected in four and four cases, respectively, whereas in OSCC, HPV 16 and 18 was detected in ten and nine cases, respectively. In all three groups, predominantly, Arg/Arg protein was present followed by Pro/Pro and Arg/Pro. Among the control, Arg/Arg type protein was frequently seen followed by Arg/Pro, Pro/Pro in the presence of HPV. OSF and OSCC were associated homologous genes in the presence of HPV.

Conclusion: The definite association between p53 codon 72, polymorphism and HPV 16 and 18 was seen in OSCC with low frequency in OSF. Frequency of homozygous genotype is at high risk in the presence of HPV 16 and 18 in developing OSCC.

Keywords: Human papillomavirus, oral squamous cell carcinoma, oral submucous fibrosis, p53

INTRODUCTION

Oral squamous cell carcinoma (OSCC) is a major disease, and it constitutes the sixth most common malignancy in the world. OSCC is often preceded by preexisting potentially malignant disorders such as oral submucous fibrosis (OSF).[1] The prevalence of OSF reported by Gupta et al. is 28.3%, which is much higher than that of leukoplakia (13.4%).[2] The disease is prevalent in the 2nd and 3rd decades with...
malignant transformation rate as high as 7.6%. The etiology associated is betel nut either in the form of betel quid or gutkha, and its etiopathogenesis is multifactorial. In addition, the high-risk human papillomavirus (HPV) is also been detected in OSF and OSCC.

HPV detection in potentially malignant and OSCC showed many discrepancies, but HPV 16 and 18 genotypes were most frequently found virus. HPV 16 associated carcinogenesis is mediated by expression of viral E6 and E7 oncoproteins which cause deregulation of the cell cycle by inactivating p53 and pRb response. Loss of function of p53 gene, that is, the tumor suppressor gene can occur by mutations by viral oncoproteins, such as E6 of HPV. HPV is a small DNA virus with over 70 different types. It plays an important role in the pathogenesis of cervical, oral and pharyngeal carcinoma. The percentage of recorded virus varies from 0% to 100%, the possible reasons for such a large variation are the use of different detection methods and differences in the populations studied. One of the major difficulties in the detection of HPV infection in oral cancer is the presence of the virus in only a subpopulation of cells and at low copy number in the infected cells, highly sensitive and controlled methods are therefore required.

To the best of our knowledge, this will be the first study to examine high-risk HPV and p53 genotypes in OSF, OSCC and control using tissue in the North Karnataka population. Our aim is to screen for high-risk HPV genotypes in tissue samples of OSF, OSCC and controls. Moreover, explore the association between p53 and HPV in OSF and OSCC patients. Further analyzed the correlation between the habit, site and clinical staging of the disease with the presence of HPV.

MATERIALS AND METHODS

Study population
All the 60 patients (30 OSFs and 30 OSCCs) included randomly from rural and urban areas have visited Oral Medicine department. Among all 30 healthy controls were age- and sex-matched individuals. The procedure and the significance of the study was explained to the patients. After thoroughly explained to them, a written consent form was obtained from the patients who were willing to participate in the study. The study was approved by the Institutional Ethical Committee Board (IRB.No. 2013/S/OP/12).

Sample collection, fixation and storage

Tissue
Punch biopsy tissue sample (20 mg) is collected, preserved and fixed in 2 ml of Eppendorf tube containing RNA later (DNA-/RNA-stabilizing solution) from all the above referred and identified individuals. The Eppendorf tube containing tissue samples were preserved and stored at −80°C deep freezer. HeLa cell lines were obtained from the National Center for Cell Sciences, Pune, India. Further, these cell lines were used as a positive control in all the polymerase chain reaction (PCR).

Genomic DNA isolation
DNeasy Tissue Kit was used to isolate the genomic DNA from OSF, OSCC and control were done and was confirmed by 0.8% of agarose gel electrophoresis; and the DNA bands were observed by gel documentation. DNA quantification was done on microvolume ultraviolet spectrophotometer (Quawell Q3000).

Primer design
Specific primers were designed for HPV consensus sequences and HPV 16 and 18 genotypes.

Electrophoresis
After the PCR amplification, the amplicons are run through 4% agarose gel electrophoresis and the DNA bands were observed in gel documentation.

Polymerase chain reaction
PCR-based detection of HPV sequences in clinical samples is done as per the standardized protocol.

Polymerase chain reaction-restriction fragment length polymorphism
a. The forward primer and reverse primer are used to amplify the region containing p53: Arg72Pro polymorphism (rs1042522)

| n | Primer sequence | 5’–3’ |
|---|----------------|-------|
| 1 | p53 F | TGCTCTTTTCACCCATCTAC |
|   | p53 R | ATACGGCCAGGCATTGAAGT |

b. PCR product is digested with 2 U of BstUI at 60°C about 4 h. DNA fragments are run on a 2% agarose gel stained with ethidium bromide. (i) The arginine (Arg) allele is cleaved by BstUI, yielding two fragments of 213 and 140 bp. (ii) The proline (Pro) allele not cleaved by BstUI and has a single 353 bp band. (iii) Heterozygotes contain all three bands, i.e., 353, 213 and 140 bp.

Following the clinical examination, the demographic details of patients were recorded in the preprepared case pro forma, and data were entered in the excel sheet for the further analysis.

RESULTS

In the present study, we noted OSF patients below 40 years of age were 80% and the patients above 40 years of age
were only 20% in comparison, and in contrast, OSCC patients above 40 years of age were 70% and the patients below 40 years were 30%. In both the groups, male predominance was observed [Table 1].

HPV presence was frequent in the control group. When the association between the individual variants and the three groups were assessed, HPV 16 and 18 combined \( (P = 0.01) \) and other type \( (P = 0.004) \) showed a statistically significant association.

In the control group, the predominantly type of virus seen was others (36.7%), followed by HPV 16 (23.3%) and HPV 18 (10%). In OSF, only 33.3% of cases showed the presence of HPV, of which HPV 16 and 18 were 13.3% and 13.3%, respectively. In contrast, OSCC samples showed 60% presence of HPV, with HPV 16, HPV 18 and both HPV 16 and 18, 33.3%, 30.0% and 13.3%, respectively. Other types of HPV were seen more in the control group, followed by OSCC and OSF. There was a statistically significant association between the presence/absence of HPV among the three groups \( (P = 0.04) \) Table 2.

Protein levels in tissue of healthy control, OSF and OSCC showed similar findings. In tissue A/A was 60% followed by A/P was 26.7% and P/P was 13.3%. Whereas in OSF and OSCC A/A was 50%, 60% followed by A/P was 26.7% and 33.3% and P/P was 23.3% and 6.7%, respectively. The difference in the proportions of protein levels among different groups was not statistically significant \( (P > 0.05) \) in both saliva and tissue Table 3.

Table 3 depicts statistically significant association between the presence/absence of HPV and the presence of a particular type of protein in controls and OSCC patients. In OSF, the frequency distribution was not statistically significant. Among the healthy controls A/A type protein was frequently seen followed by A/P, P/P irrespective of presence or absence of HPV. In the OSCC group, in the absence of HPV A/A was common followed by P/P and A/P, and in the presence of HPV P/P was common followed by A/A and A/P Table 4.

No significant association between age, gender, habit, site and clinical stage were seen with the presence or absence of HPV in tissue and distribution of proteins in the tissue.

**DISCUSSION**

In the present study, we studied the distribution of TP53 codon 72 genotypes in 30 OSF and 30 OSCC patients and 30 controls, to assess the amino acid variability and associated risk of developing the tumor. Genetic polymorphism of gene may determine the individual susceptibility for cancer. The p53 gene contains single-nucleotide polymorphism that encodes either Arg or Pro at amino acid codon 72 of p53. Individual inherits either homozygous, either (Arg/Arg) or (Pro/Pro) or heterozygous (Arg/Pro) at p53 codon.\(^6\) Homozygosity at p53 amino acid might represent a risk factor for carcinogenesis, the authors have reported that homozygous for Arg-72 is about seven times more susceptible to development of cervical cancer for than heterozygous.\(^7\) In addition, correlation between distribution of p53 genotype and prognosis of the lung, cervix and esophagus cancer has been reported. Studies in oral cancer are limited and controversial. In the present study, homozygous Arg/Arg and Pro/Pro genotypes were associated with OSCC compared to heterozygous type. Furthermore, control and OSF cases were associated

---

### Table 1: The descriptive data of the groups

| Characteristics  | Control, n (%) | OSF, n (%) | OSCC, n (%) |
|------------------|---------------|------------|-------------|
| Age (years)      |               |            |             |
| Below 40         | 23 (76.7)     | 24 (80)    | 9 (30)      |
| Above 40         | 7 (23.7)      | 6 (20)     | 21 (70)     |
| Sex              |               |            |             |
| Female           | 4 (13.3)      | 0          | 4 (13.3)    |
| Male             | 26 (86.7)     | 30 (100)   | 26 (86.7)   |
| Habit            |               |            |             |
| Habit            | -             | 30 (100)   | 18 (60)     |
| No habit         | -             | -          | 12 (40)     |
| Site             |               |            |             |
| BM               | -             | -          | 17 (56)     |
| Tongue           | -             | -          | 13 (44)     |
| HPV in tissue    |               |            |             |
| Positive         | 19 (63.3)     | 10 (33.3)  | 18 (60)     |
| Negative         | 11 (36.7)     | 20 (66.7)  | 12 (40)     |
| Types of protein |               |            |             |
| Arginine/arginine| 18 (60.0)     | 15 (50.0)  | 18 (60.0)   |
| Arginine/proline | 8 (26.7)      | 7 (23.3)   | 2 (6.7)     |
| Proline/proline  | 4 (13.3)      | 8 (26.7)   | 10 (33.3)   |

OSF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, HPV: Human papillomavirus, BM: Buccal mucosa

### Table 2: The distribution of human papillomavirus in tissue and its variants among different groups

| Groups       | HPV in tissue, n (%) | HPV 16, n (%) | HPV 18, n (%) |
|--------------|----------------------|---------------|--------------|
| Control      |                      |               |
| Absent       | 20 (36.7)            | 23 (76.7)     | 27 (90.0)    |
| Present      | 10 (63.3)            | 7 (23.3)      | 3 (10.0)     |
| Total        | 30 (100)             | 30 (100)      | 30 (100)     |
| OSF          |                      |               |
| Absent       | 20 (66.7)            | 26 (86.7)     | 26 (86.7)    |
| Present      | 10 (33.3)            | 4 (13.3)      | 4 (13.3)     |
| Total        | 30 (100)             | 30 (100)      | 30 (100)     |
| OSCC         |                      |               |
| Absent       | 12 (40.0)            | 20 (66.7)     | 21 (70.0)    |
| Present      | 18 (60.0)            | 10 (33.3)     | 9 (30.0)     |
| Total        | 30 (100)             | 30 (100)      | 30 (100)     |

\[ \chi^2 = 6.502 \]

\[ P = 0.04 \]

HPV: Human papillomavirus, OSF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma
with Arg/Arg homozygotes. Similar to our findings, homozygous type (Arg/Arg) is predominantly reported in control and OSCC.\textsuperscript{[6,8‑11]} Very few authors have reported with heterozygous type (Arg/Pro) association OSCC.\textsuperscript{[12‑15]} Brief review of distribution of the p53 codon 72 genotype among control and OSCC is given in Tables 5 and 6.

Further, we assessed the p53 codon 72 genotype and association with HPV 16 and 18 in control, OSF and OSCC. Several investigators have studied the prevalence of HPV in potentially malignant disorder, hoping to find a similar HPV prevalence as in malignant diseases. In the present study, in control group, 63.3% cases showed the presence of HPV, but they were other type than the HPV 16 and 18 types. Other authors have observed a high percentage of HPV in normal mucosa which lies in accordance with the present study.\textsuperscript{[16,17]} In contrast, many others have not found the presence of HPV in premalignant disorder suggests that it may play a role in malignant transformation. Ha \textit{et al.} reported 1% prevalence of HPV 16 and 18 in premalignant oral lesions using the quantitative PCR.\textsuperscript{[22]} On the other hand, Bagan \textit{et al.} did not find any association between HPV DNA and proliferative verrucous leukoplakia using PCR.\textsuperscript{[23]} Another study analyzed the high-risk HPV DNA in OSF and to determine the role of HPV infections. A total of 105 cases, 33 (31.4%) patients were positive for high-risk HPV, while 72 (68.6%) patients were negative.\textsuperscript{[24]} Chen \textit{et al.} reported the positivity of HPV 16 as 52.6% and HPV 18 as 25% in OSF by the PCR method.\textsuperscript{[11]} Vidal \textit{et al.} reported 72.5% negative for low- and high-risk HPV DNA, 22.5% positive for low- and high-risk HPV DNA, 2.5% positive for low-risk HPV DNA and 2.5% positive for high-risk HPV DNA in 40 oral carcinoma cases by the Hybrid Capture (HC) technique.\textsuperscript{[25]} In the present study, 33.3% HPV presence were detected in OSF using PCR including both HPV 16 and 18. Chaudhary \textit{et al.} studied and compared between the HC II test and PCR-based assay for the detection of HPV DNA in OSF and OSCC. It was noted that the overall prevalence of HPV 16 E6 DNA positivity was nearly 26% by PCR and 27.4% by the HC II assay in OSF and , 32.4% HPV 16 E6 positive by PCR, and 31.4% by the HC II assay in OSCC.\textsuperscript{[26]} Elamin \textit{et al.} detected HPV DNA in 14/28 (50%) carcinomas and 4/12 (33%) precancerous lesions using nested PCR. The detection procedure ensured sensitivity and consistency of the detection of low copy numbers of the virus DNA. It was concluded that the presence of HPV found in 33% of premalignant tissues.\textsuperscript{[3]}

In India, the presence of HPV association with OSCC seen ranged from 15% to 67%.\textsuperscript{[27]} About 67% is highest reported from Southeast India,\textsuperscript{[28]} whereas in the Japanese

### Table 3: The distribution of tissue proteins based on presence or absence of human papillomavirus among different groups

| Groups | Type of tissue proteins | Total | $\chi^2$ | $P$ |
|---|---|---|---|---|
| Control | Arginine/arginine, n (%) | 10 (55.6) | 8 (44.4) | 8 | 11 (36.7) | 7.09 | 0.02 |
| | Arginine/proline, n (%) | 1 (12.5) | 7 (87.5) | 4 (100.0) | 19 (63.3) | 30 | |
| | Proline/proline, n (%) | 0 (0.0) | 4 (100.0) | 30 | 30 | |
| OSF | HPV in tissue | Absent | 9 (60.0) | 6 (85.7) | 5 (62.5) | 20 (66.7) | 1.50 | 0.47 |
| | | Present | 6 (40) | 1 (14.3) | 3 (37.5) | 10 (33.3) | 30 | |
| | Total | 15 | 7 | 5 | 20 | 30 | |
| OSCC | HPV in tissue | Absent | 10 (55.6) | 8 (50.0) | 1 (10.0) | 12 (40.0) | 5.64 | 0.05 |
| | | Present | 8 (44.4) | 1 (15.0) | 9 (90.0) | 18 (60.0) | 30 | |
| | Total | 18 | 2 | 8 | 30 | | |

OSF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, HPV: Human papillomavirus

### Table 4: Distribution of different types of proteins in tissue in different variants of human papillomavirus among different groups

| Groups | Proteins in tissue | HPV 16 | HPV 18 |
|---|---|---|---|
| | Present | Absent | Present | Absent |
| Control | Arginine/arginine | 2 | 16 | 1 | 17 |
| | Arginine/proline | 5 | 3 | 2 | 6 |
| | Proline/proline | 2 | 2 | 0 | 4 |
| OSF | Arginine/arginine | 4 | 11 | 2 | 13 |
| | Arginine/proline | 0 | 7 | 1 | 6 |
| | Proline/proline | 0 | 8 | 1 | 7 |
| OSCC | Arginine/arginine | 4 | 14 | 4 | 14 |
| | Arginine/proline | 0 | 2 | 1 | 1 |
| | Proline/proline | 6 | 4 | 4 | 6 |

OSF: Oral submucous fibrosis, OSCC: Oral squamous cell carcinoma, HPV: Human papillomavirus
23%, USA 8%–20% and 19% Dutch population. In the present study, the frequency of HPV 16 and 18 is 33.3% and 13.3%, respectively, did not find any statistical association. The prevalence of HPV 16 is seen associated with risk of development of OSCC than HPV 18; similar findings are reported by various authors Perrone et al., D’Costa et al. and Bouda et al.\textsuperscript{[12,27,29]} Review of the studies on association between HPV and p53 codon 72 genotypes among oral cancer is detailed in Table 7.

Various studies have shown the distribution of p53 genotype and its correlation with predisposition and prognosis of cancer of cervix, lung and esophagus. The allele frequency in the present study was homozygous allele’s, i.e., AA and PP, respectively. Higher frequency of Pro allele is found in the Indian population.\textsuperscript{[14,19,22]}

The frequency of A/A, P/P and A/P genotypes in HPV-positive cases as compared to frequency for HPV-negative cases. Hamel \textit{et al.} did not find any association between p53 codon 72 polymorphism of oral cancer.\textsuperscript{[8]} However, Storey \textit{et al.} now reveal that the Arg form of p53 is more susceptible to degradation by the HPV E6 protein than in the Pro form.\textsuperscript{[7]}

Moreover, patients with HPV-associated cervical cancer are much more likely to contain the Arg form of p53 compared with the rest

---

### Table 5: Distribution of p53 codon 72 genotypes among healthy controls

| Control sample | Arginine/arginine (%) | Arginine/proline (%) | Proline/proline (%) | Author |
|----------------|-----------------------|----------------------|---------------------|--------|
| 163            | 95 (58.3)             | 61 (37.4)            | 7 (4.3)             | Hamel, 2000 |
| 308            | 168 (54.54)           | 112 (38.36)          | 28 (9.99 s)         | Summersgill, 2000 |
| 333            | 175 (52.6)            | 134 (40.2)           | 24 (7.2)            | Shen H, 2002 |
| 20             | 12 (60)               | 12 (60)              | 12 (60)             | Katiyar, 2003 |
| 77             | 84 (59.6)             | 47 (33.3)            | 10 (7.1)            | Perrone, 2007 |
| 342            | 179 (52.4)            | 140 (40.9)           | 23 (6.7)            | Jix, 2008 |
| 72             | 14 (19)               | 6 (8)                | 52 (72)             | Tindle, 2001 |
| 26             | 13 (50)               | 11 (42.3)            | 2 (7.6)             | Nagpal, 2002 |
| 349            | 181 (51.9)            | 144 (41.2)           | 24 (6.9)            | Chen |
| 94             | 21 (22)               | 51 (54)              | 22 (24)             | Chakraborty |
| 30             | 18 (60)               | 8 (26.7)             | 4 (13.3)            | Present study |

OSCC: Oral squamous cell carcinoma

### Table 6: Distribution of p53 codon 72 genotypes among oral squamous cell carcinoma cases

| OSCC           | Arginine/arginine (%) | Arginine/proline (%) | Proline/proline (%) | P     | Author |
|----------------|-----------------------|----------------------|---------------------|-------|--------|
| 163            | 88 (54.0)             | 68 (41.7)            | 7 (4.3)             | 0.50  | Hamel, 2000 |
| 190            | 102 (53.68)           | 70 (36.84)           | 18 (9.4)            | 0.77  | Summersgill, 2000 |
| 304            | 158 (52.0)            | 125 (41.1)           | 21 (6.9)            | 0.970 | Shen H, 2002 |
| 153            | 22 (14)               | 100 (65)             | 31 (20)             | -     | Katiyar, 2003 |
| 110            | 3 (28.18)             | 58 (52.72)           | 21 (19.09)          | 0.005 | Perrone, 2007 |
| 44             | 10 (22.72)            | 24 (54.54)           | 10 (22.72)          | -     | Jix, 2008 |
| 77             | 63 (81.8)             | 8 (10.4)             | 6 (7.8)             | 0.647 | Chen |
| 188            | 103 (54.8)            | 74 (39.4)            | 11 (5.8)            | 0.837 | Chakraborty |
| 326            | 183 (56.1)            | 121 (37.1)           | 22 (6.8)            | 0.519 | Present study |
| 82             | 20 (25)               | 38 (46)              | 24 (6.9)            | 0.647 | Chakraborty |
| 30             | 18 (60)               | 2 (6.7)              | 10 (33.3)           | -     | Present study |

### Table 7: Association between human papillomavirus and p53 codon 72 genotypes among oral cancer in cases and controls

| Number of cases | p53 arginine/arginine, n (%) | p53 arginine/proline, n (%) | p53 proline/proline, n (%) | Author |
|-----------------|-----------------------------|-----------------------------|-----------------------------|--------|
| HPV 16 +ve      | 25                          | 8 (32)                      | 13 (52)                     | 4 (16) | Nagpal |
| HPV 18 +ve      | 16                          | 6 (37.5)                    | 7 (43.75)                   | 3 (18.75) |
| HPV –ve         | 69                          | 17 (24.63)                  | 33 (55.07)                  | 14 (20.28) |
| HPV 16 +ve      | 16                          | 11 (80)                     | 1 (10)                      | 4      | Perrone |
| HPV 16 –ve      | 61                          | 52 (85.24)                  | 7 (11.47)                   | 2 (3.27) | Katiyar |
| HPV +ve         | 13                          | 2 (15.4)                    | 10 (76.9)                   | 1 (7.7) | Summersgill |
| HPV –ve         | 31                          | 8 (25.8)                    | 14 (45.2)                   | 9 (29.0) | Chakraborty |
| HPV +ve         | 46                          | 26 (56.5)                   | 15 (32.6)                   | 5 (10.9) | Present study |
| HPV –ve         | 154                         | 76 (52.8)                   | 65 (38.2)                   | 13 (9.0) | Chakraborty |
| HPV 16 +ve      | 101                         | 42 (40.8)                   | 45 (52.9) (combined)        | Jix |
| HPV 16 –ve      | 87                          | NA                          | NA                          | -     | Present study |
| HPV +ve         | 93                          | 48 (26.2)                   | 52 (36.4) (combined)        | 3 (16.66) | Chen |
| HPV –ve         | 226                         | 135 (52.8)                  | 91 (63.6)                   | -     | Present study |
| HPV 16 +ve      | 10                          | 4 (40)                      | 0                           | 6 (60) | Chakraborty |
| HPV 18 +ve      | 6                           | 4 (66.66)                   | 1 (16.66)                   | 1 (16.66) | study |
| HPV –ve         | 14                          | 10 (7.142)                  | 1 (7.41)                    | 3 (21.42) | Chakraborty |

NA: Not available
of the population. The authors conclude that patients with two copies of the Arg form have a sevenfold higher risk of developing cervical cancer than people with the Pro form. Shen et al. and Vidal et al. reported Pro/Pro patients reported with younger age group than Pro/Arg and Arg/Arg among oral cancer.[10,34]

Nagpal et al. observed A/P genotype in HPV-positive infection as compared to P/P genotype, indicating A/P genotype is highly susceptible to HPV infection and oral carcinogenesis.[10,16] Sixteen similar findings have been noted by Tandle et al., Katiyar et al. and Chakraborthy et al.[15,13,16] Summergill et al. did not see any association between p53 codon 72 polymorphism and HPV.

Although Makni et al. reported with interlaboratory variation in the proportion of A/A, A/P and P/P,[33] Perrone et al. speculated the protective effect of the RP genotype in oropharyngeal squamous cell carcinoma with combination of R72 and P72. R72 has a greater capacity to induce apoptosis, whereas P72 has greater transcriptional transactivation ability and induce cell cycle arrest at G1 phase. Greater frequency of PP in HPV-positive SCC indicates the risk factor of oropharynx carcinoma, whereas other study HPV-negative tumors were associated with PP genotype.[12]

Summergill et al. (2000) evaluated the association between p53 polymorphism at codon 72 and HPV infection in the oral cavity as well as its association with oral cancer. Oral squamous cells from 202 patients with oral cancer and 333 age-sex frequency-matched controls were evaluated by PCR for the presence and type of HPV and for alleles of codon 72 in p53. It was noted that p53 codon 72 polymorphism is not associated with HPV infection. In addition, no association was found with the codon 72 polymorphism and oral cancer.[9]

No statistical significant correlation was seen with age, sex, habit, distribution of site, clinical stage and grade of OSCC, indicating HPV infection is not influenced by these factors. Similar findings have been recorded by various authors,[29,30] but Paz et al. noted advanced tumors with lymph node metastasis had high HPV infection.[19] Ji and Li et al. studies showed HPV 16 seropositivity among squamous cell carcinoma of oropharynx (SCCOP) was higher among men and younger individuals.[10,34]

CONCLUSION

High-risk HPV infection 16 and 18 is observed in patients with homozygous genotypes including Arg/Arg and Pro/Pro in OSCC, apparently suggesting homozygous genotypes are at high risk than heterozygous type. We also observed potential malignant disorder, i.e., OSF did not find higher frequency of homozygous genotype is at high risk in the presence of HPV 16 and 18 in developing OSCC.

Financial support and sponsorship
The study was financially supported by Advanced Research, Rajiv Gandhi University of Health Sciences, Bengaluru. RGU: Adv. Res.: Proposal-D-46:2015-16.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Elamin F, Steingrimsdottir H, Wanakulasuriya S, Johnson N, Tavassoli M. Prevalence of human papillomavirus infection in premalignant and malignant lesions of the oral cavity in UK. Subjects: A novel method of detection. Oral Oncol 1998;34:191-7.
2. Gupta PC, Bhonsle RB, Murti PR, Daftary DK, Mehta FS, Pindborg JJ. An epidemiologic assessment of cancer risk in oral precancerous lesions in India with special reference to nodular leukoplakia. Cancer 1989;63:2247-52.
3. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol 1985;13:340-1.
4. Chaudhary AK, Singh M, Sundaram S, Mehrotra R. Role of human papillomavirus and its detection in potentially malignant and malignant head and neck lesions: Updated review. Head Neck Oncol 2009;1:22.
5. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108:766-72.
6. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Lett 2002;183:123-30.
7. Storey AJ, Thomas M, Kalita A, Harwood C, Gardiol D, Manovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
8. Hamel N, Black MJ, Ghabrial P, Foulkes WD. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 2000;82:757-9.
9. Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Tureck L. P53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:334-9.
10. Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlström KR, Schiller JT, et al. P53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis 2008;29:875-9.
11. Chen PC, Pan CC, Kuo C, Lin CP. Risk of oral premalignant lesions associated with human papillomavirus infection, betel quid chewing, and cigarette smoking in Taiwan: An integrated molecular and epidemiologic study. Arch Pathol Lab Med 2006;130:57-61.
12. Perrone F, Mariani I, Pastore E, Orsenigo M, Saardi S, Marcomini B, et al. P53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer 2007;109:2461-5.
13. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 2003;252:117-24.
14. Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer 2002;97:649-53.

15. Tandle AT, Sanghi V, Saranath D. Determination of p53 genotypes in oral cancer patients from India. Br J Cancer 2001;84:739-42.

16. Chakraborty B, Roy JG, Majumdar S, Uppala D. Relationship among tobacco habits, human papilloma virus (HPV) infection, p53 polymorphism/mutation and the risk of oral squamous cell carcinoma. J Oral Maxillofac Pathol 2014;18:211-6.

17. Miguel RE, Villa LL, Cordeiro AC, Prado JC, Sobrinho JS, Kowalski LP. Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Am J Surg 1998;176:428-9.

18. Adams V, Schmid S, Zariwala M, Schmid M, Kleihues P, Briner J, et al. Prevalence of human papilloma virus DNA in head and neck cancers carrying wild-type or mutant p53 tumor suppressor genes. Anticancer Res 1999;19:1-6.

19. Chang KW, Chang CS, Lai KS, Chou MJ, Choo KB. High prevalence of human papillomavirus infection and possible association with betel quid chewing and smoking in oral epidermoid carcinomas in Taiwan. J Med Virol 1989;28:57-61.

20. Nishioka S, Fukushima K, Nishizaki K, Gunduz M, Tominaga S, Fukazawa M, et al. Human papillomavirus as a risk factor for head and neck cancers – A case-control study. Acta Otolaryngol Suppl 1999;540:77-80.

21. Eike A, Buchwald C, Rolighed J, Lindeberg H. Human papillomavirus (HPV) is rarely present in normal oral and nasal mucosa. Clin Otolaryngol Allied Sci 1995;20:171-3.

22. Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med 2004;15:188-96.

23. Bagan JV, Jimenez Y, Murillo J, Gavalda C, Poveda R, Scully C, et al. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg 2007;65:46-9.

24. Mehrrota R, Chaudhary AK, Pandya S, Debnath S, Singh M, Singh M, et al. Correlation of addictive factors, human papilloma virus infection and histopathology of oral submucous fibrosis. J Oral Pathol Med 2010;39:460-4.

25. Vidal A, Junior A, Mello R, Branao V, Rocha G. HPV detection in oral carcinomas. J Bras Pathol Med Lab 2004;40:21-6.

26. Chaudhary AK, Pandya S, Mehrrota R, Bharti AC, Singh M, Singh M, et al. Comparative study between the hybrid capture II test and PCR based assay for the detection of human papillomavirus DNA in oral submucous fibrosis and oral squamous cell carcinoma. Virol J 2010;7:253.

27. D'Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 1998;34:413-20.

28. Balaram P, Nalinakumari KR, Abraham E, Balan A, Hareendran NK, Bernard HU, et al. Human papillomaviruses in 91 oral cancers from Indian betel quid chewers – High prevalence and multiplicity of infections. Int J Cancer 1995;61:450-4.

29. Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D, et al. “High risk” HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol 2000;13:644-53.

30. Shindoh M, Chiba I, Yasuda M, Saito T, Funaoaka K, Kohgo T, et al. Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Cancer 1995;76:1513-21.

31. Paz IB, Cook N, Odom-Mayron T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer 1997;79:595-604.

32. Cruz IB, Snijders PJ, Steenbergen RD, Meijer CJ, Snow GB, Walboomers JM, et al. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 1996;32B:55-62.

33. Makni H, Franco EL, Kaiano J, Villa Ll, Labrecque S, Dudley R, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: Effect of inter-laboratory variation. Int J Cancer 2000;87:528-33.

34. Li W, Thompson CH, Gossart YE, O’Brien CJ, McNeil EB, Scolyer RA, et al. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 2004;26:1-9.